{"preliminary_commentary":{"by_channel":{"x_thread":12,"youtube":6,"podcast":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03091192\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"SAVOIR","nct_id":"NCT03091192","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=savoir-nct03091192. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"See: intervention description","label":"Savolitinib","type":"EXPERIMENTAL"},{"description":"See: intervention description","label":"Sunitinib","type":"ACTIVE_COMPARATOR"}],"collaborators":["Hutchison Medipharma Limited"],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Carcinoma","Carcinoma, Renal Cell","Kidney Neoplasms","Urologic Neoplasms","Kidney Diseases","Neoplasms by Site","Enzyme Inhibitors","Protein Kinase Inhibitors"],"enrollment":{"count":60,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Savolitinib","otherNames":["AZD6094 (HMPL-504)/Volitinib"],"type":"DRUG"},{"name":"Sunitinib","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-14","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2019-08-18","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)","timeFrame":"RECIST tumour assessments every 6 weeks from randomisation until disease progression as defined by Recist 1.1 and confirmed by BICR."}],"references":[{"citation":"Choueiri TK, Heng DYC, Lee JL, Cancel M, Verheijen RB, Mellemgaard A, Ottesen LH, Frigault MM, L'Hernault A, Szijgyarto Z, Signoretti S, Albiges L. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Aug 1;6(8):1247-1255. doi: 10.1001/jamaoncol.2020.2218.","pmid":"32469384","type":"DERIVED"},{"citation":"Maia MC, Salgia M, Pal SK. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Nat Rev Urol. 2020 May;17(5):271-291. doi: 10.1038/s41585-020-0297-9. Epub 2020 Mar 17.","pmid":"32203306","type":"DERIVED"}],"start_date":{"date":"2017-07-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Savolitinib vs. Sunitinib in MET-driven PRCC.","url":"https://clinicaltrials.gov/study/NCT03091192"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/savoir-nct03091192"}